Sirna, Open Biosystems, Ambion

Premium

Sirna Selects HCV Drug Candidate

Sirna Therapeutics said this week that it has selected an RNAi compound for development as a hepatitis C therapeutic.

According to the company, the compound, called Sirna-AV34, is a systemically delivered, nanoparticle-based, chemically modified short interfering RNA that targets multiple sequences of the HCV genome. It is designed to inhibit viral replication and reduce the selection of drug-resistant mutant variants.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Popular Mechanics reports that Caltech researchers have built a prototype nanobot using DNA.

The Sacramento Bee writes that direct-to-consumer genetic testing connected a woman to sperm donor-conceived half siblings.

In PLOS this week: gene expression catalog for sheep, viral diversity among respiratory samples from camels, and more.